MA
TCRT icon

Mutual Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Mutual Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-181
Closed -$1.92K – 1131
2023
Q4 		$1.92K Hold
181
– – ﹤0.01% 1003
2023
Q3 		$3.57K Hold
181
– – ﹤0.01% 968
2023
Q2 		$13.8K Hold
181
– – ﹤0.01% 991
2023
Q1 		$17.1K Buy
181
+34
+23% +$3.24K ﹤0.01% 963
2022
Q4 		$14.3K Hold
147
– – ﹤0.01% 912
2022
Q3 		$38K Sell
147
-100
-40% -$29K ﹤0.01% 862
2022
Q2 		$46K Hold
247
– – ﹤0.01% 817
2022
Q1 		$24K Buy
247
+13
+6% +$1.67K ﹤0.01% 856
2021
Q4 		$38K Buy
234
+118
+102% +$25.9K ﹤0.01% 879
2021
Q3 		$32K Buy
+116
New +$35.5K ﹤0.01% 859

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Mutual Advisors's TCRT Position: Q1 2024 in Review

Mutual Advisors sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 181 shares — an estimated $1.92K sold.

Mutual Advisors first reported a position in TCRT in Q3 2021 and held it in 10 quarters. The position peaked at $46K in Q2 2022. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Mutual Advisors reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Mutual Advisors sold 181 Alaunos Therapeutics shares in Q1 2024, an estimated $1.92K.
  • Mutual Advisors first reported a position in Alaunos Therapeutics in Q3 2021 and held it in 10 quarters.
  • Mutual Advisors's Alaunos Therapeutics position peaked at $46K in Q2 2022.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Mutual Advisors's 13F filing for Q1 2024, filed 2 May 2024.